PRINCETON, N.J., Jan. 04, 2021 (Globe NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ:IART), a main worldwide health care technological know-how enterprise, nowadays introduced it has accomplished its previously announced divestiture of its Extremity Orthopedics enterprise to Smith+Nephew (LSE:SN, NYSE:SNN).
“With this divestiture, we will now be in an even more robust position to capitalize on our core solutions and technologies in neurosurgery and regenerative medicine, and offer higher price to our shoppers and shareholders,” mentioned Peter Arduini, president and CEO, Integra LifeSciences. “We want to thank the orthopedics workforce for their contributions to Integra’s good results and would like them all the finest for their long term.”
Piper Sandler & Co. is serving as monetary advisor and Morgan, Lewis & Bockius LLP is performing as legal advisor to Integra.
About Integra LifeSciences
Integra LifeSciences is a worldwide chief in regenerative systems and neurosurgical alternatives devoted to restricting uncertainty for clinicians, so they can aim on offering the very best affected individual treatment. Integra gives a comprehensive portfolio of significant top quality, leadership manufacturers that include things like AmnioExcel®, Bactiseal®, Certas®, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, SurgiMend®, TCC-EZ®, and VersaTru®. For the latest news and facts about Integra and its products and solutions, you should go to www.integralife.com.
This news release is made up of ahead-searching statements, including statements about our present-day and long term performance in the that means of the Non-public Securities Litigation Reform Act of 1995 that include hazards and uncertainties, and reflect the Company’s judgment as of the date of this release. Ahead-hunting statements involve, but are not constrained to, these that incorporate text this sort of as “estimate,” “will,” “plan,” “should,” “expect,” “continue,” and “forecast”. Ahead-searching statements also include things like, but are not minimal to, statements relating to future economic overall performance, including projections for revenues. It is essential to note that the Company’s targets and anticipations are not predictions of actual efficiency. These types of ahead-wanting statements include dangers and uncertainties that could trigger precise outcomes to differ materially from predicted or envisioned success. This sort of threats and uncertainties consist of, but are not constrained to, chance aspects and uncertainties recognized below the heading “Risk Factors” included in Item 1A of Integra’s Yearly Report on Kind 10-K for the year ended December 31, 2019 and data contained in subsequent filings with the Securities and Exchange Commission.
These forward-on the lookout statements are designed only as of the day hereof, and the Corporation undertakes no obligation to update or revise the ahead-on the lookout statements, no matter if as a outcome of new information, future activities, or otherwise.
Trader Relations Get in touch with
Director, Trader Relations
Media Get in touch with:
Senior Director, International Company Communications